Key result
Dabigatran 150 mg twice daily was cost-effective compared to genotype-guided warfarin therapy in patients with atrial fibrillation, with an incremental cost-effectiveness ratio of USD13,810 per QALY gained.
Why the study?
Is dabigatran or genotype-guided warfarin management more cost-effective for stroke prevention in 65-year-old patients with atrial fibrillation?
Population
Hypothetical cohort of 65-year-old patients with newly diagnosed atrial fibrillation and CHADS2 score of 2…
Comparison
Dabigatran 110 mg or 150 mg twice daily, or… vs Standard warfarin dosing with usual…
Design
Other
Follow-up
Life-long (simulated up to 25 years)
Authors
Loading...
Dabigatran 150 mg appears cost-effective versus genotype-guided warfarin at modeled TTR; leaves open whether real-world TTR >77% favors genotype-guided care.
Is dabigatran or genotype-guided warfarin management more cost-effective for stroke prevention in 65-year-old patients with atrial fibrillation?
Effect estimate: ICER USD13,810
Absolute Event Rate: 10.065% vs 9.554%
Dabigatran 150 mg is highly cost-effective compared to genotype-guided warfarin therapy for stroke prevention in atrial fibrillation, unless genotype-guided management can achieve a time in therapeutic range >77% with comparable quality of life.
You et al. (2012) studied Atrial Fibrillation. Dabigatran vs. Genotype-guided warfarin therapy was evaluated on Incremental cost per quality-adjusted life-year (QALY) gained (ICER USD13,810). Dabigatran 150 mg twice daily was cost-effective compared to genotype-guided warfarin therapy in patients with atrial fibrillation, with an incremental cost-effectiveness ratio of USD13,810 per QALY gained.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: